Bright Minds Biosciences | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ian McDonald(30.56%)
Bright Minds Biosciences | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ian McDonald(8.88%)
Bright Minds Biosciences | 6-K: Report of foreign private issuer (related to financial reporting)
Bright Minds Biosciences | SC 13D: Statement of acquisition of beneficial ownership by individuals-Ian McDonald(7.57%)
Bright Minds Biosciences: FY2023 Annual Report
Bright Minds Biosciences | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Bright Minds Biosciences | 6-K: Bright Minds Announces Non-Brokered Private Placement Fully Subscribed By Management
Bright Minds Biosciences | 6-K: Condensed Consolidated Interim Financial Statements for the three and nine months ended June 30, 2023 and 2022
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Positive qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences | 6-K: Bright Minds Announces Effective Date of Share Consolidation
Bright Minds Biosciences | 6-K: Bright Minds Announces Proposed Share Consolidation
Bright Minds Biosciences | 6-K: MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2023
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Bright Minds Biosciences | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Bright Minds Biosciences | 6-K: Bright Minds Biosciences to Hold Annual General Meeting on March 24, 2023
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Bright Minds Biosciences | 6-K: Bright Minds Biosciences Announces Non-Executive Director Appointment
Bright Minds Biosciences | 6-K: BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY LETTER REGARDING INDEPENDENT DIRECTOR AND AUDIT COMMITTEE REQUIREMENTS
Bright Minds Biosciences | 6-K: Condensed Consolidated Interim Financial Statements and Management's Discussion and Analysis
No Data